Milena Ferro1, Gabriella Macchia2, Alessia Re2, Milly Buwenge3, Marica Ferro2, Mariangela Boccardi2, Vincenzo Picardi2, Anna Ianiro4, Eleonora Arena2, Alice Zamagni3, Eleonora Farina5, Savino Cilla4, Vincenzo Valentini6, Alessio Giuseppe Morganti3, Francesco Deodato7. 1. Radiation Oncology Unit, Gemelli Molise Hospital, Catholic University of Sacred Heart, Largo A. Gemelli 1, 86100 Campobasso, Italy. Electronic address: milena.ferro@gemellimolise.it. 2. Radiation Oncology Unit, Gemelli Molise Hospital, Catholic University of Sacred Heart, Largo A. Gemelli 1, 86100 Campobasso, Italy. 3. Radiation Oncology Center, Dept. of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna, S. Orsola-Malpighi Hospital, 40138 Bologna, Italy. 4. Medical Physics Unit, Gemelli Molise Hospital, Catholic University of Sacred Heart, Largo A. Gemelli 1, 86100 Campobasso, Italy. 5. Radiation Oncology Unit, Maria Cecilia Hospital, GVM Care & Research, 48033 Cotignola, Italy. 6. Radiotherapy, Radiology and Hematology Department - Gemelli ART (Advanced Radiation Therapy), Policlinico Universitario "A. Gemelli", Catholic University of Sacred Heart, 00168 Rome, Italy; Istituto di Radiologia, Catholic University of Sacred Heart, 00168 Rome, Italy. 7. Radiation Oncology Unit, Gemelli Molise Hospital, Catholic University of Sacred Heart, Largo A. Gemelli 1, 86100 Campobasso, Italy; Istituto di Radiologia, Catholic University of Sacred Heart, 00168 Rome, Italy.
Abstract
OBJECTIVES: To assess the feasibility and safety of a repeated SHort course Accelerated RadiatiON therapy (SHARON) regimen in the palliative setting of Head and Neck (H&N) cancer in older adults. MATERIAL AND METHODS: Patients with histological confirmed H&N cancers, age ≥ 80 years, expected survival >3 months, and Eastern Cooperative Oncology Group (ECOG) performance status of ≤3 were enrolled. Patients were treated in cohorts of six patients: a total dose of 20 Gy was delivered in 2 consecutive days with a twice-daily fractionation (5 Gy per fraction) and at least 8-h interval. If no Grade 3 toxicity was registered, a second enrollment started with another cohort of six patients to whom were administered two cycles (total dose of 40 Gy). The primary endpoint was to evaluate the feasibility of the two cycles of treatment. Secondary endpoints were evaluation of symptoms control rate, symptoms-free survival (SFS), and Quality of Life (QoL) scores. RESULTS: Seventeen consecutive patients (median age: 85 years) were treated. Nine patients were treated with one cycle and 8 patients with two cycles. No G3 toxicity was reported in either cohort. With a median follow-up time of 4 months, 3-month SFS in the first and second cohorts was 83.3%, and 87.5%, respectively. The overall palliative response rate was 88%. Among 13 patients reporting pain, 8 (61.5%) showed an improvement or resolution of their pain. CONCLUSION: Repeated short course accelerated radiotherapy in a palliative setting of H&N cancers is safe and well-tolerated in older adults.
OBJECTIVES: To assess the feasibility and safety of a repeated SHort course Accelerated RadiatiON therapy (SHARON) regimen in the palliative setting of Head and Neck (H&N) cancer in older adults. MATERIAL AND METHODS: Patients with histological confirmed H&N cancers, age ≥ 80 years, expected survival >3 months, and Eastern Cooperative Oncology Group (ECOG) performance status of ≤3 were enrolled. Patients were treated in cohorts of six patients: a total dose of 20 Gy was delivered in 2 consecutive days with a twice-daily fractionation (5 Gy per fraction) and at least 8-h interval. If no Grade 3 toxicity was registered, a second enrollment started with another cohort of six patients to whom were administered two cycles (total dose of 40 Gy). The primary endpoint was to evaluate the feasibility of the two cycles of treatment. Secondary endpoints were evaluation of symptoms control rate, symptoms-free survival (SFS), and Quality of Life (QoL) scores. RESULTS: Seventeen consecutive patients (median age: 85 years) were treated. Nine patients were treated with one cycle and 8 patients with two cycles. No G3 toxicity was reported in either cohort. With a median follow-up time of 4 months, 3-month SFS in the first and second cohorts was 83.3%, and 87.5%, respectively. The overall palliative response rate was 88%. Among 13 patients reporting pain, 8 (61.5%) showed an improvement or resolution of their pain. CONCLUSION: Repeated short course accelerated radiotherapy in a palliative setting of H&N cancers is safe and well-tolerated in older adults.
Authors: Daniel R Dickstein; Eric J Lehrer; Kristin Hsieh; Alexandra Hotca; Brianna M Jones; Ann Powers; Sonam Sharma; Jerry Liu; Vishal Gupta; Loren Mell; Zain Husain; Diana Kirke; Krzysztof Misiukiewicz; Marshall Posner; Eric Genden; Richard L Bakst Journal: Cancers (Basel) Date: 2022-06-05 Impact factor: 6.575
Authors: Ajay T Bakas; Aniel Sewnaik; Jaclyn van Straaten; Robert J Baatenburg de Jong; Francesco U S Mattace-Raso; Harmke A Polinder-Bos Journal: Clin Interv Aging Date: 2021-09-16 Impact factor: 4.458
Authors: Alessio G Morganti; Gabriella Macchia; Francesco Cellini; Francesco Deodato; Alice Zamagni; Giambattista Siepe; Milly Buwenge Journal: Front Oncol Date: 2022-02-23 Impact factor: 6.244
Authors: Alexander Fabian; Justus Domschikowski; Anne Letsch; Claudia Schmalz; Sandra Freitag-Wolf; Juergen Dunst; David Krug Journal: JAMA Netw Open Date: 2022-09-01
Authors: Alexander Fabian; Justus Domschikowski; Markus Hoffmann; Oliver Weiner; Claudia Schmalz; Jürgen Dunst; David Krug Journal: Front Oncol Date: 2021-06-04 Impact factor: 6.244